Therapy Areas
AbCellera signs multi-year collaboration and license agreement with Everest Medicines
23 September 2021 -

Canada-based biotechnology company AbCellera (Nasdaq: ABCL) has signed a multi-year collaboration and license agreement with Everest Medicines Limited (HKEX 1952.HK), a biopharmaceutical company, to discover therapeutic antibodies for up to 10 targets chosen by Everest Medicines, it was reported on Wednesday.

The collaboration is intended to provide support in expanding Everest's range of novel medicines across multiple indications, with the initial programs concentrating on targets in oncology.

By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access. The collaboration will leverage the full breadth of AbCellera's technology stack, including sourcing fully humanised antibodies from the Trianni Mouse, sourcing single domain antibodies from camelids, and combining any two antibodies to create native bispecifics using the OrthoMabTM protein engineering platform.

According to the terms of the contract, Everest will have the rights to develop and commercialise antibodies resulting from the partnership. AbCellera is to receive research payments and is eligible to receive from Everest downstream clinical and commercial milestone payments and royalties on net sales of products.